Sertacream*crema 30g 2%

NAME
SERTACREAM 2% CREAM

PHARMACOTHERAPEUTIC CATEGORY
Topical antifungals - imidazole and triazole derivatives.

ACTIVE PRINCIPLES
100 grams of cream contain: sertaconazole nitrate 2 g.

EXCIPIENTS
Polyethylene glycols and ethylene glycol-palmito stearates (Tefose 63), polyoxyethylenated lauropalmitostearic glycerides (Labrafil M-2130-CS), glycerol mono-diisostearate, vaseline oil, methyl parahydroxybenzoate, sorbic acid, purified water.

INDICATIONS
Topical treatment of cutaneous mycoses such as dermatophytosis, Tinea pedis, Tinea capitis, Tinea cruris, Tinea corporis, Tinea barbae and Tinea manus; Candidiasis (Moniliasis) and Pytiriasis versicolor (Malassezia furfur, Pityrosporum orbiculare).

CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substance or to any of the excipients.

DOSAGE
The use of the product is reserved for adult patients. Average recommended dose: the cream should be applied lightly and evenly once or twice a day on the affected areas, also covering about 1 cm of surrounding healthy skin. The quantity to be applied is variable and in relation to the extent of the diseased area. The duration of treatment to achieve healing varies from patient to patient, depending on the causative agent and location of the infection. In general, 4 weeks of treatment are recommended to ensure complete healing, although in many cases clinical-microbiological healing occurs between the second and fourth week.

STORAGE
Store at a temperature not exceeding 25 degrees C, in a dry place, in the original package to protect the medicine from light.

WARNINGS
Do not use for ophthalmic treatments. There are currently no studies on the use of the drug in pediatrics. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. The product contains methyl p-hydroxybenzoate: slightly irritating to the skin, eyes and mucous membranes.

INTERACTIONS
No interactions with other substances have been reported.

SIDE EFFECTS
No toxic or photosensitizing effects have been reported to date. During the first days of treatment, no case of local and transient erythematous reaction was evidenced, such as to have to interrupt the treatment. There may be episodes of local irritation (such as burning and itching).

PREGNANCY AND BREASTFEEDING
After topical application of large quantities of the drug no trace of it has ever been found in the plasma; despite this, the perfect harmlessness in pregnant women has not yet been demonstrated, therefore the risk / benefit ratio must be evaluated before applying the product during pregnancy and lactation.